biontech
report
third
quarter
financial
results
operational
update
november
mainz
germany
november
globe
newswire
biontech
se
nasdaq
bntx
biontech
company
announce
financial
results
third
quarter
tuesday
november
biontech
invites
investors
general
public
join
conference
call
webcast
investment
analysts
day
edt
cet
report
financial
results
provide
corporate
update
third
quarter
slide
presentation
audio
webcast
available
via
following
link
https
mmc
p
jqhpczzu
participate
conference
call
please
dial
following
numbers
ten
minutes
prior
start
provide
conference
id
united
states
international
united
states
domestic
germany
conference
id
participants
may
also
access
slides
webcast
conference
call
via
events
presentations
page
investor
relations
section
company
website
https
replay
webcast
available
shortly
conclusion
call
archived
company
website
days
following
call
biontech
biopharmaceutical
new
technologies
next
generation
immunotherapy
company
pioneering
novel
therapies
cancer
serious
diseases
company
exploits
wide
array
computational
discovery
therapeutic
drug
platforms
rapid
development
novel
biopharmaceuticals
broad
portfolio
oncology
product
candidates
includes
individualized
therapies
innovative
chimeric
antigen
receptor
cells
checkpoint
targeted
cancer
antibodies
small
molecules
based
deep
expertise
mrna
vaccine
development
manufacturing
capabilities
biontech
collaborators
developing
multiple
mrna
vaccine
candidates
range
infectious
diseases
alongside
diverse
oncology
pipeline
biontech
established
broad
set
relationships
multiple
global
pharmaceutical
collaborators
including
genmab
sanofi
bayer
animal
health
genentech
member
roche
group
regeneron
genevant
fosun
pharma
pfizer
information
please
visit
biontech
contacts
investor
relations
sylke
maas
investors
